• Home
  • Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.

Author List
Shah NJ, Sura SD, Shinde R, Shi J, Singhal P, Perini RF, Motzer RJ
Publication
Urologic oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/432739033
Publication Year
2023
PubMed ID
37722984
Publication Title
Shah NJ, Sura SD, Shinde R, Shi J, Singhal P, Perini RF, Motzer RJ. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. Urol Oncol. 2023 Sep 16.